D-0097-2023 Class II
FDA drug recall D-0097-2023 was initiated by Pfizer Inc. on Dec 29, 2022 and is designated Class II. Reason for recall: Lack of assurance of sterility: Bags have the potential to leak. Affected quantity: 62,088 bags.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 11, 2023
- Initiation Date
- Dec 29, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 62,088 bags
Product description
Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,
Reason for recall
Lack of assurance of sterility: Bags have the potential to leak.
Distribution pattern
Nationwide in the USA.
Code information
Lot: 5935283, Exp. 12/01/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0097-2023
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.